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Further, lipid lowering may not be as beneficial in advanced disease. We compared sur- 
vival associated with statin therapy in CAD pts with and without LVD. 
Methods: A cohort of 2,202 non-LVD pts and 364 LVD pts with angiographically defined 
CAD (270% stenosis), were studied from the registry of the Intermountain Heart Collab- 
orative Study at LDS Hospital. Risk factors and clinical data, including statin prescription 
at discharge, were recorded at baseline. Pts were followed for 3.0+1.9 years (maximum 
7.7 years) to determine the incidence of mortality. Cox regression and Kaplan-Meier esti- 
mates were used to model survival in both groups. 
Results: Patient age (63+12 years) and gender (34% female) did not differ between the 
groups. Statins were prescribed at discharge for 28% of non-LVD and 26% of LVD pts 
(p=NS). Among non-LVD patients, mortality was 6.6% for statin prescribed pts and 
12.7% for those not prescribed statins (p=O.O05 by log-rank); among LVD pts, mortality 
was 16.0% when prescribed statins and 32.6% when no statin was prescribed (p=O.O17 
by log-rank). After adjustment for covariables. these associations remained for non-LVD 
pts (hazard ratio [HR]= 0.66,95% Cl= 0.47-0.93), and LVD pts (HiX0.57, Cl= 0.33-0.99). 
No interaction was found between statin prescription and EF for moriality (p-interac- 
tiow0.71). 
Conclusion: Proportionate benefit from statin prescription was similar in LVD and non- 
LVD groups, but absolute benefit was greater in LVD pts (16% vs. 6% absolute mortality 
reduction). These results demonstrate the benefit of statin discharge prescription, 
regardless of degree of LVD and emphasize current underutilization, particularly in those 
with LVD. 
before 12h 24h lweek 
SBP(mmHg) 92*13 96+12’ 95*16 96+14 
Cl (Vmin/mz) i.7ko.3 2.4+0.4’ 2.5+0.6 2.5*0.6’ 
PCWP (mmHg) 26+6 25+6 23+6’ 22*10’ 
RA (mmHg) 15t6 11*5’ 1 O-t6* 1 Ok6 
SVR (IU Wood) 19a7 14*5’ 14*4 14*5 
-p&u5 versus basellne 
Conclusion: The addition of levosimendan had a sustained-therapeutic effect in clini- 
cally unstable patients with CHF refractory to continuous dobutamine and furosemide 
infusions. This regimen could be used as a bridge to left ventricular assist device implan- 
tation or heart transplantation. 
1184-79 Acute Intravenous Ranolazine Improves Lefl Ventricular 
Function in Dogs With Heart Failure: A Dose Escalation 
Study 
Hideaki Morita, George Suzuki, Margaret P. Chandler, William C. Stanley, Brent K. 
Blackbum. Hani N. Sabbah, Henry Ford Health System, Detroit, MI. Case Western 
Reserve University, Cleveland, OH 
Background: To explore the use of intravenous (iv) ranolazine. a partial fatty acid oxida- 
tion inhibitor, as acute therapy for heart failure (HF), we determined the effects of up-titra- 
tion and reversibility of ranolazine in 6 dogs with microembolizations-induced HF. 
Methods: Ranolazine was given as 0.05 mg/kg bolus followed by iv infusion at 0.1, 0.3, 
1.0 and 3.0 mgkglhr each for 1 hour. Heart rate (HR), peak left ventricular (LV) systolic 
pressure (LVSP). stroke volume (SV), LV end-diastolic volume (EDV), LV end-systolic 
volume (ESV). LV ejection fraction (EF) and ranolazine plasma concentration (RANc) 
were measured at baseline and at the end of each dose. Results: The results are shown 
in the table. Ranolazine decreased ESV without affecting EDV. thus increasing EF at all 
doses in a dose and RANc deoendent manner. The increase in EF olateaued at doses 
X.3 mgikglhr, suggesting a half maximal response at -0.1 mg/kg/hr at RANc of 67+11 
no/ml. Ranolazine had nominal effects to reduce HR at doses >0.3 ma/ka/hr and LVSP at 
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1184-77 Utilization of ACE-I and B-blocker Therapy in Managed 
Care Patients With Heart Failure: NC ACE Project 
David C. Gaff. Carfa A. Sueta, David W. Brown, Jill McArdle, Sharon Peacock, Alain 
Bertoni, Wake Forest University School of Medicine, Winston-Salem, NC, Medical 
Review of North Carolina, Gary, NC 
Background: Heart failure (HF) results in substantial morbidity and mortality in the US. 
Despite evidence-based guidelines recommending proven therapies, translation into clin- 
ical practice is suboptimal. The goal of the North Carolina Achieving Cardiac Excellence 
(NC ACE) Project is to increase the utilization of angiotensin converting enzyme inhibitor 
(ACE-l) and @blocker therapies in patients with HF. The purpose of this study is to com- 
pare the management of Medicare and Medicaid patients with HF enrolled in managed 
care. 
Methods: Data were abstracted from outpatient medical records for 971 Medicare (3 
managed care plans) and 654 Medicaid (2 plans) patients treated for HF during 2000. 
Patients receiving dialysis were excluded. 
Results: Compared to Medicaid patients, Medicare patients were older (76i3 vs. 59*14 
years), more likely to be white (64 vs. 47%), and men (50 vs. 30%). More than 80% of 
Medicare (n=795) and Medicaid (n=526) patients had documentation of a quantitative or 
qualitative assessment of left ventricular function (LVF). Left ventricular systolic dysfunc- 
tion (LVSD) was present in 37% (n=297) of Medicare patients and 37% (n=197) of Med- 
icaid patients. 
Indicator Medicare Medicaid 
LVF Assessment 849 (67%) 573 (63%) 
ACE-I in LVSD 215 (72%) 147 (75%) 
ACE-l Intolerance 42 (14%) 23 (12%) 
bblocker in LVSD 144 (46%) 96 (43%) 
eblocker Intolerance 34 (12%) 25 (13%) 
Conclusion: Assessment and treatment of HF appears similar in Medicare and Medicaid 
managed care patients. Although not optimal, these rates are substantially higher than 
previously reported. Opportunities for increasing appropriate use of &blockers should be 
prioritized in these populations. 
1184-78 Hemodynamic Effects of Levosimendan in Addition to 
Dobutamine Infusion in Patients With Advanced Heart 
Failure Intractable to Dobutamine Infusion Alone 
Panaqiotis Pavazoqlou, Maria Anastasiou-Nana, Eleftheria Tsagalou, John Terrovitis. 
Elias Tsolakis. Argirios Dalianis, George Alexopoulos. John Kanakakis, Konstantinos 
Chrfstodoulou, John N. Nanas, University of Athens, Athens, Greece 
Background: Levosimendan is a new calcium-sensitizing agent with positive inotropic 
and vasodilatory effects. 
Purpose: This study measured the magnitude and duration of the hemodynamic 
response to an infusion of levosimendan In clinically unstable patients with advanced 
congestive heart failure (CHF) pretreated with dobutamine and furosemide. 
Methods: In thirteen patients with advanced CHF. 48-77 years of age, in NYHA func- 
tional class IV, previously treated with intermittent dobutamine infusions, and hospital- 
ized for clinical instability despite continuous dobutamine. lOpg/kg/min. and furosemide, 
10 mglh, infuslons, a continuous infusion of levosimendan, in a bolus of 6 kgikg, followed 
by a 0.2 W/kg/min infusion for 24 h. was added. The patients were followed for 7 days, 
including serial right-heart catheterizations. The effect on Systolic Blood Pressure (SBP), 
Cardiac Index (Cl), Pulmonary Capillary Wedge Pressure (PCWP), Right Atrial Pressure 
(RA) and Systemic Vascular Resistance (SVR), before and at 12 hours, 24 hours and 1 
week after levosimendan administration, was recorded. 
Results: The results are summarized in the Table 
I  _  
a dose of 3.0 mglkglhr. The effect of ranolazine (0.05 mglkg bolus + 0.3 mg/kg/hr for 1 
hr) declined after stopping infusion in proportion to RANc. Conclusions: Intravenous 
ranolazine improves LV function in dogs with chronic HF in a reversible, dose and con- 
centration dependent manner with little or no impact on HR and LVSP. 
RanolazineDose (mglkglhr) 
Baseline 0.1 0.3 1 .o 3.0 
HR (beats/min) 83+4 80_+6 75_+5’ 74+5 73 i 5’A 
LVSP (mmHg) 9623 102~4 9723 9423 89 _+4’” 
SV (ml) 19+1 23_+1’ 25_+1’” 2621.” 26_+1’” 
EDV (ml) 6624 6623 6524 66+3 6524 
ESV (ml) 4724 43_+4* 41_+3’” 39+3^” 3923’” 
EF (%) 30~2 36_+2’ 36 22’” 33 + 3’” 33 -+ 3.” 
RANc (ng/ml) 0 67i4 106+94 557 i a7 1259_+1354 
*=PcO.O5 vs. Baseline; “=PcO.O5vs. 0.1 mglkglhr 
1184-80 Effect of the Angiotensin Converting Enzyme Inhibitor 
Trandolapril on Functional Status and Furosemide 
Consumption in Patients With Reduced Left Ventricular 
Function After Myocardial Infarction 
Jawdat Abdulla, Lars Kober, Christian Tarp-Pedersen, Gentofte University Hospital of 
Copenhagen, Copenhagen, Denmark 
Background: lnformatlon on the direct benefit of angiotensin converting enzyme inhibi- 
tors on symptoms are scarce and in contrast to the overwhelming amount of information 
on survival. Effect of the use of concommitant diuretic therapy on symptoms has been 
also questioned. Therefore we studied development of New York Heart Association 
(NYHA) classification and use of furosemide in the Trandolapril Cardiac Evaluation Study 
(TRACE). 
Methods: In TRACE 1749 consecutive patients with left ventricular systokc dysfunction 
after myocardial infarction (MI) were randomized to either placebo or trandolapril. The 
patients were assessed for changes in NYHA classes and use of furosemide every 3 
months and were followed up 2-4 years. 
Results: There were no differences in baseline characteristics between the two treatment 
groups. The majority of the patients were in NYHA classes II and I. Both placebo and 
trandolapril groups showed equal improvement in NYHA classes without any significant 
differences (P> 0.05, figure). This result was also found in patients with NYHA class II or 
greater at the time of randomization. Trandolapril resulted in a mild but significant reduc- 
tion of the use of furosemide with a mean reduction of 12 mg/day overall during follow up 
(pcO.001, figure). 
Conclusion: Despite a significant reduction in mortality, trandolapril did not improve 
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NYHA classes in patients with left ventricular dysfunction after MI. Trandolapril resulted 
in significantly lower furosemide consumption. 
expression of TlMPs is unchanged while expression of MMPP and 9 is increased. Ther- 
apy with ER-MET does not influence TlMPs but reduces expression of MMPP and 9, a 
finding consistent with reduced RIF following chronic therapy with the ER-MET. 
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I 184-81 Elevated Plasma Xanthine Oxidase Activity in Chronic 
Heart Failure: Source of Increased Oxygen Radical 
Load and Effect of Allopurinol in a Placebo Controlled, 
Double Blinded Treatment Study 
Wolfram Ooehner, Margaret M. Tarpey, Darrell V. Pavitt, Aidan P. Bolger. Roland 
Wensel, Stephan van Haehling, David A. Reaveley, Stefan D. Anker, National Heart & 
Lung Institute, London, United Kingdom, University of Alabama, Birmingham, AL 
Background: Elevated xanthine oxidase (X0) activity contributes to production of reac- 
tive oxygen species. Hyperuicemia is common in chronic heart failure (CHF), however, 
enzyme activity of circulating plasma X0 has not been studied in CHF. We hypothesised, 
that plasma X0 activity is elevated in CHF compared to healthy controls, paralleled by 
increased free radical load, and that X0 inhibition with allopurinol decreased both. As a 
marker of free radical load serum allantoin was measured, which is generated in the 
humans exclusively via non-enzymatic oxygen radical dependent “rate oxidation. 
Methods: In 67 CHF patients (mean age 65+1Oy, NYHA 2.4+0.7. peak VQ 16.6+6.6 
ml/kg/min) and 15 controls (age 33+1Oy) we measured plasma X0 activity (HPLC), uric 
acid (UA), and allantoin (gas chromatography-mass spectrometfy). In 17 CHF patients 
with known hyperuricemia (UA 517+95Fmol/L), the effect of allopurinol (300mg od for 1 
week) was tested in a placebo controlled double-blinded, cross-over study. 
Results: CHF patients were hyperuricemic (UA 461*14~mol/L; normal range 210440 
pmol/L) and had increased plasma X0 activity (7.01*0.60 vs 0.69e1.23 vs wU/ml; 
pcO.001). The upper limit of normal was defined as 3.35 fiU/ml X0 (normal mean value 
+2SD). All but one control and 11 patients (16%) had normal plasma X0 activity, but 56 
patients (64%) had elevated X0 activity (Chi* p<O.OOOl). Allantoin was elevated in CHF 
compared to reference control values (4l.Ot26.2 vs 13.4k1.6 pmol/L). In the double- 
blinded allopurinol treatment study, plasma X0 activity was reduced in all 17 patients by 
49% (from 4.35i 2.7* to 2.2&l .3, p<O.OOl). Allopurinol also reduced allantoin levels by 
16% (from 25.7i4.1 to 21 .l+l.O. ~~0.02). 
Conclusion: The activity of circulating plasma X0 is elevated in patients with CHF. 
Treatment with allopurinol results in reduction of X0 activity that is paralleled by lower 
allantoln indicating reduced oxygen radical load. Thus, a potentially new therapeutic 
option emerges to reduce oxygen radical load in CHF. 
1184-82 Chronic Monotherapy With Extended Release 
Metoprolol Succinate Attenuates mRNA Gene 
Expression for MMPP and MMPS in Dogs With Heart 
Failure 
Sharad Rastoa, Ramesh C. Gupta, Sudhish Mishra, Hideaki Morita, George Suzuki, 
Sidney Goldstein, Hani N. Sabbah, Henry Ford Health System, Detroit, Ml 
Background: Accumulation of collagen in the cardiac interstitium or “reactive interstitial 
fibrosis” (RIF) occurs in heart failure (HF) and contributes to LV dysfunction and remodel- 
ing. Matrix metalloproteinases (MMPs) are upregulated in HF and contribute to RIF. We 
previously showed that therapy with extended release metoprolol succinate (ER-MET) 
sianificantlv reduces RIF in doas with HF. In this studv. we examined the effects of 
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chronic therapy with ER-MET on gene expression of MMPP and MMP9 (gelatinases) and 
on tissue inhibitors of MMPs (TlMPsl in LV of doos with microembolization-induced HF. 
Methods: Total RNA was isolated from LV tissue of 14 dogs with HF randomized to 3 
months therapy with ER-MET (50 mg, once daily, n=7) or to no therapy at all (n=7) and 
from LV of 6 normal (NL) dogs. mRNA expression for MMPP and 9 and TlMPt and 2 was 
measured using reverse transcriptase polymerase chain reaction and bands quantified in 
densitometric units. Results: Results are shown in the table. There were no differences 
in expression of TlMPl and 2 among the 3 study groups. Expression of MMPP and 9 was 
increased in untreated-HF dogs compared to NL. ER-MET significantly reduced this 
increase in expression of MMPP and 9. Conclusions: In dogs with HF, mRNA gene 
TIMPl 
TIMPP 
MMPP 
MMP9 
2.33 0.35 + 2.93 + 0.46 1.90+0.38 
1.31 0.04 + 1.39 + 0.02 1.35 0.06 + 
1.30+0.16 2.04 + 0.11’ 1.39 + o..ow 
1.2220.14 2.50 + 0.04’ 1.15+0.1w 
*=P<O.O5 vs. NL; A=P<O.O5 vs. HF-Untreated 
1184-83 Dietary Fish Oil Supplementation Improves Endothelial 
Function in Patients With Congestive Heart Failure 
David R. Moraan, Lana J. Dixon, Colm G. Hanratty. Sinead M. Hughes, William J. 
Leahey, Naglaa A. El-Sherbeeny, G. Dennis Johnston, Gary E. McVeigh. Queen’s 
University Belfast, Belfast, United Kingdom 
Background 
Systemic vasoconstriction and reduced peripheral perfusion are hallmarks of congestive 
heart failure (CHF). Endothelial dysfunction is a frequent finding in CHF and is associ- 
ated with reduced bioavailability of the vasodilator auto&d nitric oxide (NO). Omega-3. 
fatty acids (fish oils) have been shown to have beneficial effects on endothelial function 
and vascular responses in a number of vascular diseases which may be secondary to 
increased NO bioavailability. We conducted a study to establish whether addition of 
omega9- fatty acids to background therapy in patients with CHF would improve endot- 
helial dysfunction. 
Methods 
20 patients with grade II and Ill CHF (15 male) mean age 73 were recruited. Sodium 
nitropmsside (SNP) (6. 9, 12nmolImin) and acetylcholine (ACH) (120,160, 240nmollmin) 
were infused into the non-dominant brachial artery. Forearm blood flow (FABF) 
responses assessed by venous occlusion plethysmography. Patients received fish oil or 
olive oil drink for 6 weeks in a double blinded randomised cross over trial with assess- 
ment of FABF at baseline and after each treatment. 
Results 
See table 
Conclusion 
Dietary fish oil significantly improved endothelial function as assessed by FABF 
responses to ACH. There are several possible mechanisms by which fish oils could 
potentially improve endothelial function in CCF. Further studies are required to attempt to 
elucidate the mechanism for this improvement and to establish whether will be associ- 
ated with improved outcomes. 
Forearm Blood Flow responses to infusion of SNP and ACH (values are arbitary units) 
(*=p<o.ol) 
SNP ACH 
Baseline 1 14.22 (10.93,17.51) 7.95(4.81,11.60) 
Fish oil 11.66 (6.17,15.15 11.27 (7.31.15.23) 
Baseline 2 13.55 (10.74,16.36) 7.66 (4.95,10.41) 
Olive oil 14.36 (11.67,17.09) 7.27 (4.66,9.66) 
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1185-59 Acute Rejection in Human Heart Transplantation: 
Identification and Characterization of Two Important 
Markers (MIP-1 p and VE-Cadherin) 
Ana L. S. Roussoulieres Olivier Raisky, Lara Chalabreysse. George Dureau, Catherine 
Cerutti. Pascale Boissonnat, Laurent Sebbag, Jean-Paul Gare. Jean-Franpois Obadia, 
Jean Ninet, Olivier Bastien, FranCoise Thivolet-Bejui. John L. McGregor, H6pital 
Cardiologique Louis Pradel, Lyon, France, INSERM, Lyon, France 
Background: An extensive number of molecules are involved in acute rejection (AR) fol- 
lowing heart transplantation. We have previously identified by DNA arrays, in a murine 
model of heterotopic heart transplantation, a number of genes implicated in allograft AR. 
The expression of 2 of these genes, MIP-lp and VE-Cadherin, was investigated in the 
present study as potential new markers of AR in cardiac tissue following human heart 
transplantation. 
Methods: We have previously studied the expression profile of genes involved in AR 
